Clinical Trials Logo

Clinical Trial Summary

Intranasal nasal steroid sprays are the mainstay of treatment for chronic Eustachian tube dysfunction despite having little supportive evidence in the literature. A novel, commercially available nasal spray delivery system is available now for fluticasone that improves its delivery to the nasopharynx. The hypothesis of this study is that fluticasone using the novel spray system is effective for Eustachian tube dysfunction (ETD).


Clinical Trial Description

BACKGROUND AND RATIONALE Eustachian tube dysfunction (ETD) can be a symptom of allergic rhinitis, non-allergic rhinitis, or chronic rhinosinusitis. However, it can also be a separate entity with patients displaying no other symptoms of the previously mentioned diseases. There is currently no FDA- approved medication specifically for eustachian tube dysfunction, but most otolaryngologists, allergists, and primary care physicians employ multiple different over-the-counter and prescription medications for its treatment. Most common are oral and topical antihistamines, nasal steroid sprays, topical and oral decongestants, and oral steroids. Nasal steroid sprays, which are FDA-approved for allergic rhinitis, are most frequently used for chronic ETD despite a lack of large clinical trials to support their use. These sprays do have good safety profiles, are frequently available over-the-counter, and do have good data on their efficacy in rhinitis and sinusitis. Fluticasone nasal spray is available over the counter and is a nasal steroid spray. It is frequently recommended or prescribed for chronic eustachian tube dysfunction. However, its efficacy and the efficacy of all nasal sprays may be limited by the access of previously available sprays into the nasopharynx. The level of evidence for these sprays in chronic ETD is poor overall with only one randomized controlled trial in adults. This study determined no benefit over placebo. In studies determining the deposition of nasal sprays, most of the spray is deposited in the front of the nasal cavity over the inferior turbinates and very little gets into the sinus cavities or nasopharynx. A new exhalational delivery system fluticasone spray (EDS-FLU) has been FDA-approved for patients with chronic rhinosinusitis with polyps. The main difference between this spray and previously available sprays is that it penetrates deeper into the sinuses and also to the nasopharynx, the location of the eustachian tubes. In this system, the user blows out while pumping the spray bottle and his/her breath is the driving force of the spray bottle. Blowing out also elevates the soft palate, seals the nasopharynx, and contains all the spray into the nasal cavity, sinuses, and nasopharynx. In a traditional spray, the soft palate is at resting position, and the spray can pass through the nasal cavity and down into the oropharynx and mouth. This is typically perceived by many users as postnasal drip after the use of nasal sprays. The investigators have previously published a retrospective review of the use of EDS-FLU in patients with at least 1 month of ETD symptoms and found that 79% had improvement more than the minimal clinically important difference. Thirty-six percent of patients normalized with regards to symptoms, and 80% of patients with pre- and post-treatment tympanometry normalized their tympanogram. This study will compare placebo to fluticasone exhalational nasal spray system (Xhance) in a randomized, controlled study. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05275686
Study type Interventional
Source Cedars-Sinai Medical Center
Contact Missael Vasquez
Phone 424-315-2437
Email missael.vasquez@cshs.org
Status Recruiting
Phase Phase 2
Start date April 20, 2022
Completion date January 2025

See also
  Status Clinical Trial Phase
Completed NCT04776967 - Effect of Total Compression Time and Rate (Slope) on Incidence of Symptomatic ETD and MEB: A Phase II Prospective Study. N/A
Recruiting NCT04804098 - Effect of Rate (Slope) of Compression on the Incidence of Symptomatic ETD and MEB: a Phase III Prospective Study. N/A
Terminated NCT01974726 - Gas Supply, Demand and Middle Ear Gas Balance -- Diagnosis of Eustachian Tube Dysfunction N/A
Recruiting NCT05600595 - The Evaluation of Eustachian Tube Function and Its Influencing Factors After Snoring Operation in Children
Not yet recruiting NCT05998356 - Long-term Assessment of Balloon Eustachian Tuboplasty for Obstructive Eustachian Tube Disease N/A
Not yet recruiting NCT03322579 - Balloon Dilation of the Eustachian Tube, a Lower Pressure Challenge N/A
Withdrawn NCT03886740 - Tympanostomy Tubes Versus Eustachian Tube Dilation N/A
Completed NCT04809753 - Eustachian Tube Dilation With an Endovascular Balloon N/A
Withdrawn NCT02631187 - Feasibility Study of Balloon Eustachian Tuboplasty (BET) N/A
Completed NCT04902963 - What is the Tympanic Membrane Healing Time After Insertion of a Gelfoam PE Tube? N/A
Completed NCT04136977 - XprESS ET Registry
Completed NCT03197558 - Adult Study to Evaluate Placement of Tympanostomy Tubes In-office (ADEPT) Phase 2
Recruiting NCT05719207 - Efficacy of Balloon Dilation of the Eustachian Tube in Eustachian Tube Dilatory Dysfunction N/A
Completed NCT01251432 - Risk Factors and Potential Causes of Eustachian Tube Dysfunction in Adults N/A
Recruiting NCT04645511 - Balloon Sinuplasty Efficiency in Maxillary Rhinosinusitis. N/A
Recruiting NCT05055115 - Ph.D.-Project: Eustachian Tube Dysfunction: Causes, Diagnosis, Treatment, and Prognosis N/A
Not yet recruiting NCT05222230 - FFP3 Respirators and Ears - Effects on Middle Ear Pressure and Hearing N/A
Completed NCT02667301 - Eustachian Tube Dysfunction Assessment N/A
Not yet recruiting NCT05229380 - Pretympanoplasty Assessment of Patency and Mucociliary Function of Eustachian Tube
Completed NCT03850197 - Tubomanometry and EarPopper Devices for Eustachian Tube Function Testing